J Korean Med Assoc Search

CLOSE


J Korean Med Assoc > Volume 53(6); 2010 > Article
Kim: The Pharmacotherapy of Inflammatory Bowel Disease in Child and Adolescence

Abstract

The importance of pediatric inflammatory bowel disease (IBD) has grown significantly, for the incidence of pediatric inflammatory bowel disease in Korea has been rapidly increasing in recent years. One quarter of the new IBD patients has been known to be presented in childhood. Growth and pubertal delay are one of key factors in the management of pediatric IBD. The focus of treatment in children should be to reduce or eliminate symptoms, optimize nutritional status and growth, and prevent complications. This review will deal with the evidence supporting the treatments currently used in children with inflammatory bowel disease.

References

1. Kim BJ, Song SM, Kim KM, Lee YJ, Rhee KW, Jang JY, Park SJ, Yoon CH. Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: A single-center experience. Dig Dis Sci 2009;(Epub ahead of print).

2. Suh HA, Kim SE, Jang JY, Kim BJ, Kim JS, Lee SY, Chang SH, Kim KM. Efficacy of nutritional therapy in children with Crohn disease. Korean J Pediatr Gastroenterol Nutr 2006;9:210-217.

3. Kim KM. The treatment of pediatric inflammatory bowel disease. Korean J Pediatr Gastroenterol Nutr 2008;11:S. 72-79.

4. Song SM, Jang JY, Kim KM. Nutritional status of childhood onset inflammatory bowel disease. Clinical Nutrition 2008;196(A).

Table 1
Summary of dosage, indications, and side effects of drugs for the treatment of inflammatory bowel disease in children
jkma-53-524-i001-l.jpg

Abbreviations; CD: Crohn's disease, UC: Ulcerative colitis



ABOUT
ARTICLE CATEGORY

Browse all articles >

ARCHIVES
FOR CONTRIBUTORS
Editorial Office
37 Ichon-ro 46-gil, Yongsan-gu, Seoul
Tel: +82-2-6350-6562    Fax: +82-2-792-5208    E-mail: jkmamaster@gmail.com                

Copyright © 2024 by Korean Medical Association.

Developed in M2PI

Close layer
prev next